COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leading digital health company specializing in AI-driven cardiometabolic health, today announced significant advancements in its AI research strategy, focused on responsible AI integration in healthcare. The company presented a series of clinical publications on the application of its novel generative AI model designed to improve health outcomes through predictive analytics at leading industry conferences throughout October, including FNCE, DTM and INFORMS. This research expands upon Welldoc's impressive portfolio of 37 AI-focused publications, solidifying the Company’s leadership in developing responsible and judicious AI solutions for healthcare.
Welldoc's evolving strategy prioritizes investment in AI-driven clinical research and partnerships with leading public, academic and private partners. This collaborative approach fosters diversity and breadth in their datasets, enabling more robust predictive analytics to support deeply personalized health progress and outcomes. Additionally, Welldoc's expertise in navigating regulatory oversight of AI-enabled solutions positions the Company to bring these offerings to individuals living with complex cardiometabolic conditions like diabetes.
"We believe that when AI is properly tested and integrated into care models, it has the potential to transform the continuum of care, personalize the cardiometabolic health journey and help providers optimize clinical decisions," said Anand Iyer, PhD, MBA, Chief AI Officer of Welldoc. "Welldoc's AI is illuminating novel insights across risk and clinical outcomes by harnessing the power of advancements in real-time sensor data and an individual's unique health journey."
Welldoc's AI research has centered around predicting outcomes, such as weight, and leveraging the power of real-time sensors, like continuous glucose monitors (CGM), to provide meaningful insights for complex condition support. Recent research from Welldoc, presented at FNCE, used AI-modeling and Shapley analysis to predict at least 3% weight loss with 93% accuracy, as well as the effect of variables like nutrients and time-based correlations. Another publication, presented earlier this fall at MLHC, revealed a new generative large sensor model (LSM) capable of predicting future glucose levels 50% more accurately than current state-of-the-art approaches. As real-time sensor innovations become more accessible and affordable, the need for digital health solutions that translate this data into personalized, predictive insights will be crucial in order to guide individuals toward better health.
"Emerging metrics like time in tight range (TITR) and glucose risk index (GRI) are essential for understanding an individual's glucose control, but what's often missing is the personalized guidance needed to achieve optimal levels for these metrics," said David Klonoff, MD, CEO of Diabetes Technology Society. "Models like Welldoc's, that use AI, are enabling the delivery of invaluable insights and coaching to guide individuals’ actions around activity, nutrition and medication regimens so they can optimize these health measures.”
Welldoc is being recognized for its leadership in both AI and digital health, with the Company being selected as a winner of the 2024 Healthcare AI Impact Awards, MedTech Breakthrough Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. Additionally, Anand Iyer was recently named to Constellation Research’s AI 150 list and was invited to speak at their inaugural AI Summit, as well as at leading AI conferences like Frontiers Health in Berlin and Global Digital Health Summit in Mumbai.
Welldoc will be hosting a webinar on AI in healthcare featuring industry experts, as well as other upcoming educational events. To sign up to receive updates, visit www.welldoc.com/updates
For more information on Welldoc’s latest AI-focused research, visit www.welldoc.com/clinical-research
About Welldoc
Welldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc’s comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc’s flagship product, BlueStar®, is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. These capabilities are now integrated into the Welldoc platform, providing comprehensive and flexible support across conditions. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs.
Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 48 patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the “Best Overall Digital Health Company” by MedTech Breakthrough for the past two years, and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit www.welldoc.com. Follow us on LinkedIn and Twitter.
